Market capitalization | $562.32m |
Enterprise Value | $527.56m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.04 |
P/S ratio (TTM) P/S ratio | 2.18 |
P/B ratio (TTM) P/B ratio | 2.72 |
Sales growth (TTM) Sales growth | 28.23% |
Turnover (TTM) Turnover | $258.47m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
5 Analysts have issued a Pharming Group N.V. - ADR forecast:
5 Analysts have issued a Pharming Group N.V. - ADR forecast:
Mar '24 |
+/-
%
|
||
Turnover | 55 55 |
30%
30%
|
|
Gross income | 47 47 |
22%
22%
|
|
EBITDA | -11 -11 |
11%
11%
|
EBIT (operating result) EBIT | -17 -17 |
16%
16%
|
Net profit | -12 -12 |
1%
1%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
Head office | Netherlands |
CEO | Sijmen Vries |
Founded | 1988 |
Website | www.pharming.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.